Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “PLACENTAL EXTRACTS”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 307 records · Page 17Linked to original sources
PubMedDate not supplied

Placental expression of insulin-like growth factor receptor-1 and insulin receptor in the growth-restricted fetal rat.

OBJECTIVE: The type 1 insulin-like growth factor receptor (IGF-R1), which resembles the insulin receptor (INS-R), is expressed abundantly in the placenta. The regulation of fetal growth by IGFs and insulin might reflect their actions on the placenta. This study compared the placental expression of IGF-R1 and INS-R in growth-restricted and normal pregnancies. METHODS: Fetal growth restriction was produced in Sprague-Dawley rats by bilateral ligation of the uterine artery on day 19 (term = 21.5 days). Fetuses were delivered by hysterotomy on day 20, and placental samples were frozen. Fetuses that had been subjected to a sham operation of maternal laparotomy without uterine artery manipulation were studied as matched controls. IGF-R1 and INS-R message was assessed by reverse transcription and polymerase chain reaction amplification of extracted placental RNA. The receptors also were assessed by Western blotting of extracted placental protein. Measurements for the growth-restricted group were expressed as a multiple of that of the matched sham litter. RESULTS: Placental IGF-R1 messenger RNA (mRNA) level was significantly lower in the growth-restricted fetuses (0.66 x sham [0.47-0.93], P <.05), but INS-R mRNA was not different (0.89 x sham [0.63-1.3], P >.5). IGF-R1 protein transcript was similarly reduced in the growth-restricted fetuses (0.78 x sham [0.69-0.88], P <.005), but the INS-R protein transcript was not (0.98 x sham [0.69-1.4], P >.8). Birth weights were significantly less in the growth-restricted group (3.06 +/- 0.07 versus 3.29 +/- 0.06 g, P =.016); placental weights were not (0.54 +/- 0.02 versus 0.54 +/- 0.02 g, P =.90). CONCLUSIONS: The placenta responds to decreased nutrient delivery with decreased expression of IGF-R1. This would reduce the growth-promoting effects of insulin-like growth factors, which include augmentation of placental lactogen production and glucose and amino acid transport. INS-R was unaffected, which suggests that placental response to insulin is less important than its response to insulin-like growth factors in growth restriction.

Animals↗
PubMed1986

Gonadotropin-releasing hormone-like immunoreactivity in rat placenta.

The concentration of gonadotropin-releasing hormone (GnRH) in the placenta, maternal plasma and fetal hypothalamus was measured in rats during days 13-21 of gestation. A substantial amount of GnRH was detectable in the extract of placenta and maternal plasma samples collected between days 13 and 21 and in the extract of fetal hypothalamus collected between days 19 and 21 of pregnancy. The GnRH level in the placenta and fetal hypothalamus, but not in plasma, fluctuated significantly during pregnancy. The level of GnRH gradually decreased in the placenta but increased in the fetal hypothalamus as the pregnancy proceeded. After gel filtration of placental extract, GnRH eluted in the same position as synthetic GnRH and hypothalamic GnRH. Dilution of placental extracts produced a displacement curve parallel to that of GnRH and hypothalamic extracts. These results indicate that GnRH is present in the placenta and that placental GnRH may have a role in the maintenance of pregnancy in rats.

Animals↗
PubMed1985

Effects of placenta and maternal serum on prolactin secretion in vitro.

The effects of the placenta and maternal sera on the secretion of prolactin (Prl) were examined in vitro. Placentae were obtained on each of Days 8-11 of pregnancy and extracted in 2.0% butanol-saline. To determine if these extracts could inhibit Prl secretion in vitro, dispersed anterior pituitary cells were incubated with placental extracts containing 1.0 placental equivalent obtained on each of Days 8-11 of pregnancy. Prl secretion was not affected by extracts of placentae obtained on Day 8 but was significantly inhibited by placental extracts obtained on Days 9-11 of pregnancy. In fact, progressively more mature placentae induced greater degrees of Prl inhibition. Extracts of placentae that were obtained on each of Days 8-11 of pregnancy, normalized on the basis of protein and tested for a 24-h period in the dispersed pituitary bioassay, caused the same degree of inhibition over Prl release. Additionally, placental protein from any given day (Days 8-11) of pregnancy induced a highly significant dose-dependent inhibition over Prl secretion. Equivalent amounts of a nonspecific protein, bovine serum albumin, had no effect. These findings indicate that the placenta does indeed contain a Prl inhibitory factor whose specific activity remains relatively constant between Days 8 and 11 of pregnancy. To determine if the inhibitory activity is humoral, maternal sera collected on each of Days 8-11 of pregnancy were placed in culture with dispersed pituitary cells at a concentration of 15.0%. Concomitant with gestational maturity, there was a progressively greater inhibition of Prl release. These findings indicate that the placenta may secrete a substance into the blood which suppresses Prl release directly at the level of the pituitary gland.

Animals↗
PubMed1994

Elution profiles and molecular weights of placental cystine aminopeptidase in animals.

Gel filtration was performed for cystine aminopeptidase (CAP) [EC 3.4.11.3] on full term placental extracts from human, cynomolgus monkey, dog, goat, pig and horse. The enzymatic profiles of CAP were examined and compared with that of CAP in pregnancy plasma on the basis of inhibitory effects. Elution profiles of placental extracts exhibited 2 CAP activity peaks in human and pig, 3 peaks in cynomolgus monkey, dog and goat, and 4 peaks in horse. The molecular weights of placental CAP that showed identical inhibitory effects to that of pregnancy plasma CAP were estimated to be approximately 325,000 in human, 350,000 in the cynomolgus monkey, 140,000 in the dog, 140,000 in the goat, 128,000 in the pig, and 115,000 in the horse. These molecular weights tended to decrease in accordance with the increase of barrier layers present between maternal blood and placental syncytiotrophoblasts in which CAP is synthesized.

Animals↗
PubMed1980

Human placental oxytocinase and its relationship to pregnancy plasma oxytocinase.

Plasma "oxytocinase of pregnancy" and three placental "oxytocinase" fractions from human placental extracts were compared. On the basis of acrylamide-agarose chromatography, polyacrylamide gel electrophoresis, substrate specificity, heat liability and relative insensitiveness to L-methionine, it is concluded that placental enzyme activities, present in the second acrylamide-agarose peak, are identical with the plasma "pregnancy oxytocinase" and are to be regarded as its source. The hypothesis of a transplacental passage of placental peak II oxytocinase in the blood compartment of the mother seems well supported. Heat treatment of the placental extracts uncovered a minor activity behaving like Oya's microsomal oxytocinase, which is totally unlike the plasma oxytocinase and plays no part in the increased oxytocinase activity of human pregnancy plasma. A hitherto undescribed enzyme activity shares with the pregnancy oxytocinase its specificity towards L-leucyl-beta-naphthylamide and di-S-S-L-cysteinyl-beta-naphthylamide, its heat lability and realtive insensitiveness to L-methionine. However, this activity is carried by a protein of much lower molecular weight as judged by acrylamide-agarose chromatography, which shows only a single activity band on polyacrylamide gel electrophoresis.

Acid Phosphatase↗
PubMed1990

Soluble and membrane-associated human low-affinity adenosine binding protein (adenotin): properties and homology with mammalian and avian stress proteins.

A low-affinity adenosine binding protein has recently been distinguished from the adenosine A2 receptor and purified from human placental membranes. Soluble human placental extracts contain an adenosine binding activity that has properties similar to those of the membrane low-affinity adenosine binding protein. The binding protein was purified from soluble human placental extracts 134-fold to 89% purity with a Bmax of 2.5 nmol/mg. It comprises 0.7-0.9% of the soluble protein. The major purified soluble protein has a subunit molecular mass of 98 kDa and a Stokes radius identical with that of the membrane-bound adenosine binding protein. Competition analysis of the soluble protein revealed similar affinities and an identical potency order for displacement of 5'-(N-ethylcarbamoyl)[2,8-3H]adenosine ([3H]NECA) as follows: NECA greater than 2-chloroadenosine greater than adenosine greater than (R)-N6-(2-phenylisopropyl)adenosine. The soluble binding protein was more acidic than the membrane binding protein as revealed by a comparison of the elution properties during ion exchange chromatography. A second form of soluble adenosine binding activity comprised 17% of the major form and had a charge similar to that of the membrane binding protein, a smaller Stokes radius, and a subunit molecular mass of 74 kDa. Carbohydrate composition analysis revealed that the major soluble form has 4.3% carbohydrate by weight as compared to the membrane-associated form, which has 5.5% carbohydrate by weight.(ABSTRACT TRUNCATED AT 250 WORDS)

Amino Acid Sequence↗
PubMed1981

Human placentas contain a specific inhibitor of RNA-directed DNA polymerase.

Human placental extracts contain a specific inhibitor of mammalian retroviral RNA-directed DNA polymerase (deoxynucleosidetriphosphate:DNA deoxynucleotidyltransferase, EC 2.7.7.7) activity. This inhibitor copurifies with retrovirus-like particles in human placental extracts. The inhibitor can be removed from these particles by salt extraction, which leads to the recovery of the polymerase activity. Thus, the inhibitor does not irreversibly inactivate the particle-associated RNA-directed DNA polymerase activity. The inhibitory preparation contained no nuclease, protease, or phosphatase activity. Because its inhibitory action can be eliminated by the addition of more virus to the reaction, nonspecific inactivation of enzyme substrate has been ruled out. A partial characterization of the inhibitor indicates that it is (i) insensitive to ether, trypsin, and phospholipase C; (ii) stable to heat and pH 2-12; and (iii) nondialyzable.

Female↗
PubMed1981

The similarity of chorionic gonadotrophin and its subunits in term placentae from man, apes, old and New World monkeys and a prosimian.

Chorionic gonadotrophin (CG) was estimated, by bioassay and radioimmunoassay (RIA), in placental extracts from 11 ape and monkey species. There was a significant correlation between the results of the two assay systems (r = 0.903, p less than 0.001). The concentration of CG in most primate term placentae was the same as that in the human placenta at term. Extracts from all placentae cross-reacted with antiserum to ovine LH-beta subunit, and those of the chimpanzee and gorilla also had a significant cross-reaction with an antiserum to the carboxyl terminal peptide of the HCG-beta subunit. Primate placentae chromatographed on Sephadex G-200 had components active in the RIA systems for HCG, HCG-alpha HCG-beta subunits. In general, the elution profiles of all ape and monkey placental extracts resemble those made from human term placentae and of purified HCG and its subunits. The shape of the elution patterns from human and non-human material suggests that there was more than one molecular form of CG-alpha subunit activity. A second, more retarded molecular form having beta subunit activity was found in extracts made from human, gorilla, gibbon and rhesus monkey placentae. The similarity between the structure of ape and monkey placental CG with HCG and its subunits implies a function similar to that of HCG in late pregnancy.

Animals↗
PubMed1981

Lipolytic and enkephalinase inhibitory activities of polypeptides from placental autolysate prepared for therapeutic purposes.

In order to study the pharmacodynamic basis of therapeutic uses of placental extracts researches was carried out on Sephadex G25 factors of autolytic extract of human placenta. Four of these fractions showed immunoreactivity for both beta-endorphin and ACTH, and were able to stimulate lipolysis in rabbit adipose tissue. An inhibition of the enkephalinase activity of rat brain homogenates was displayed by placental fractions of low molecular weight. These results suggest that beta-endorphin and ACTH play a roles in the pharmacological activity of placental extracts.

Adrenocorticotropic Hormone↗
PubMed1986

Gonadotrophin in the term placenta of the dolphin (Tursiops truncatus), the Californian sea lion (Zalophus californianus), the grey seal (Halichoerus grypus) and man.

Chorionic gonadotrophin activity in extracts of the term placenta of a dolphin, a sea lion and a grey seal was measured by its effectiveness in increasing uterine weight in the mouse and by solid-phase RIA using hCG as immunogen and labelled antigen. Bioreactive (B) gonadotrophin was found in these placentae and, compared to the human term placenta, the concentration of CG in the dolphin was higher, in the sea lion similar and in the grey seal lower. The biological activity in each species was neutralized with a rabbit anti-hCG serum. All placental extracts contained material active in the hCG immunoassay (I). The ratio B/I was significantly higher for the CG in the placental extracts of the marine mammals compared with that of the human term placenta. Results of in-vivo bioassay, RIA, electrophoretic and gel-chromatographic studies indicate structural similarities between CG in the placentae of the marine mammals and human CG.

Animals↗
PubMed1994

A comparison of the metabolic profiles of fetal and maternal plasma and placenta in normal and diabetic rats by 1H magnetic resonance spectroscopy.

Spectral analysis of spin-echo 1H magnetic resonance spectroscopy (MRS) data has revealed differences in the metabolic profiles of maternal and fetal plasma and placental extracts. Resonances from low-molecular weight components of the normal maternal and fetal plasma were attributed to glucose, lactate, creatine, citrate, amino acids and ketone bodies. There were also signals from lipoprotein molecules associated with lipid-transporting moeties contained in the plasma. The placental extract showed a similar composition to the plasma samples however the spectra were dominated by a large signal attributed to betaine, there was also an absence of signals from citrate, acetoacetate, acetone and lipoproteins. Diabetes caused profound changes in all tissue types indicating high levels of glucose and ketogenic activity. In both the maternal and fetal plasma there were increases in glucose, ketone bodies and valine in the diabetic rats, increases in lactate and alanine were confined to the fetal plasma and placenta. This study indicates that diabetes causes major changes in the composition of fetal plasma which in turn could interfere with the development of the fetus.

Amino Acids↗
PubMed1987

Corticotropin releasing hormone- and adreno-corticotropin-like immunoreactivity in human placenta, peripheral and uterine vein plasma.

The presence of corticotropin releasing hormone (CRH)-like immunoreactivity (IR) in human placenta and maternal peripheral blood has been reported by many investigators. However, its physiological role has not yet been defined. We investigated plasma and placental tissue from women at different times of pregnancy and performed peripheral and uterine vein sampling during caesarean section before and after removal of the placenta. Beside IR-CRH, IR-GRF and -GnRH as well as -ACTH and cortisol were measured. The highest content of CRH was found in placental extracts from end term (40 weeks) pregnancies and lower levels at an earlier stage (10 weeks). Plasma CRH from peripheral blood could be detected in some samples and was higher as pregnancy advanced. Thirty minutes after removal of the placenta CRH levels dropped in peripheral plasma and could not be detected in uterine vein samples. IR-ACTH plasma levels were within the range of normals, cortisol was elevated. Gel- and HPLC-chromatographie revealed that placental extracts coeluted with synthetic human CRH. The material from endterm placenta showed full bioactivity in the rat pituitary bio-assay. IR-GRF could only be detected in 10 weeks placental tissue and no IR-GnRH was measured. We conclude that CRH from the placenta is biologically active, however, cannot stimulate the maternal pituitary-adrenal-axis.

Adrenocorticotropic Hormone↗
PubMedDate not supplied

Placental products induce suppressor cells of graft versus host reaction.

Cells from mice alloimmunized in the presence of placental extract were coinjected with cells from mice conventionally alloimmunized in the footpad of virgin female recipients. The contralateral footpad received a control twice the dose of cells from alloimmunized mice. Cells from the popliteal lymph nodes were harvested on day 3, and pulsed in vitro for measurement of proliferative capacity with 3H thymidine. The response of lymph nodes was compared (homo- vs contralateral). The cells from mice alloimmunized with placental extract in conjunction with alloantigens displayed a marked suppressive capacity of the local graft versus host (GVH) potential of cells from mice conventionally alloimmunized. It is suggested that this local GVH assay represents a quick, objective assay for suppressor-cell induction by placental products.

Animals↗
PubMed1994

Inhibin and follistatin concentrations in fetal tissues and fluids during gestation in sheep: evidence for activin in amniotic fluid.

The concentrations of inhibin and follistatin in amniotic fluid and in tissue extracts from the placenta, gonads and adrenals of fetal sheep were measured using radioimmunoassays. These tissue extracts were from whole fetuses from days 16 to 45 and from the individual organs from day 46 to 145 (term) and were assayed at multiple dilutions. The capacity of these extracts to alter FSH production of rat anterior pituitary cells in culture was also assessed at multiple dilutions. Immunoactive inhibin concentrations in amniotic fluid from both sexes increased during gestation and levels were significantly greater in males than females. Peak concentrations of immunoreactive inhibin of 11.2 +/- 1.9 ng/ml were found in males at 116-125 days of gestation. Follistatin concentrations did not change throughout gestation and no significant difference was noted between sexes. Mean follistatin levels throughout gestation were 3.0 +/- 0.9 ng/ml for males and 3.7 +/- 0.9 ng/ml for females. Despite the potential for FSH inhibition by inhibin and follistatin, amniotic fluid from both sexes at all stages of gestation stimulated FSH secretion in the pituitary cell bioassays, suggesting the presence of activin which was confirmed by the measurement of immunoactive activin (13.3 +/- 2.5 ng/ml) in a specific radioimmunoassay. Maximum concentrations of immunoactive and bioactive inhibin in placental extracts were observed in late gestation (2.2 +/- 0.6 and 3.8 +/- 1.6 ng/g respectively) and there was no significant difference between sexes. Follistatin concentrations in placental cotyledons ranged from 11.5 to 27.1 ng/g with no significant difference between sexes. In view of the higher follistatin concentrations compared with inhibin, it is likely that the capacity of placental extracts to suppress FSH production by pituitary cells in culture is due predominantly to follistatin. Immunoactive inhibin was observed in high concentrations in the fetal testis throughout gestation; with concentrations increasing to a maximum of 1993.0 +/- 519.7 ng/g at 126-135 days of gestation with a ratio of bioactive: immunoactive inhibin of 1:20. Although bioactive and immunoactive inhibin was also observed in fetal ovaries and adrenals from both male and female fetuses, concentrations were lower than those observed in fetal testes. Follistatin concentrations in the fetal testis were elevated between 70 and 95 days (97.6 ng/g) and then declined. Similar concentrations were found in the adrenal glands of both sexes (males 83.5-103.3 ng/g: females 55.3-95.8 ng/g).(ABSTRACT TRUNCATED AT 400 WORDS)

Activins↗
PubMed1988

Metabolism of cortisol and cortisone in the baboon fetus at midgestation.

The metabolism of cortisol (F) and cortisone (E) in the fetal circulation is likely to influence the availability/biological potency of these corticosteroids and hence maturation of fetal organ systems. Therefore, we determined the MCR, production, peripheral interconversion, and placental extraction of F and E in the baboon fetus at midgestation. Radiolabeled F and E were infused into a femoral vein of fetuses (n = 7; 4 female, 3 male) exteriorized on day 100 of gestation (term = day 184). The MCR of F in the fetus (5.6 +/- 0.8 1/day) was lower (P less than 0.01) than that of E (13.1 +/- 2.2 1/day). Placental extraction of F (72.8 +/- 5.3%) and E (87.8 +/- 2.4%) were extensive indicating that the placenta contributes to fetal F/E MCR. Although the serum concentration (micrograms per dl) of F (20 +/- 2) exceeded (P less than 0.01) that of E (12 +/- 1), the calculated production rate (milligrams per day) of F (1.09 +/- 0.12) was not significantly different from that of E (1.55 +/- 0.27). The transfer constant for fetal conversion of F to E (29.0 +/- 6.0%) exceeded (P less than 0.01) that for reduction of E to F (1.8 +/- 0.4%). Therefore, the proportion of total F production derived from circulating E was only 2.2%, whereas the proportion of E derived from circulating F was 26.7%. These findings demonstrate that at midgestation the baboon fetus has minimal capacity for peripheral conversion of biologically inactive E to biologically active F, whereas the reverse conversion (F to E) is substantial.

Animals↗
PubMed1992

Changes in bioactive and immunoactive inhibin levels around human labor.

The changes in bioinhibin (B-inhibin) and immunoinhibin (I-inhibin) levels were studied in the serum of healthy term pregnant women by ovine pituitary cell culture and immunoenzymatic assay systems before and 24 h after delivery. In the maternal serum, a sharp decline in both B-inhibin and I-inhibin levels was observed within first 6 h after delivery. B-inhibin and I-inhibin in maternal serum were 3.45 +/- 0.25 and 3.77 +/- 0.43 U/mL, respectively, before labor and decreased by 35.82% and 38.89% 30 min after labor. One hour after delivery, B-inhibin and I-inhibin were reduced by 56.74% and 61.48%, respectively. After 6 h, B-inhibin and I-inhibin levels were lowered by 93.86% and 78.90%, respectively. Twenty-four hours later, both inhibins were nearly undetectable. In the retroplacental serum, B-inhibin and I-inhibin were 4.92 +/- 0.34 and 10.13 +/- 1.16 U/mL, respectively, i.e. 42.48% and 168.60% higher than the levels of B-inhibin (P less than 0.05) and I-inhibin (P less than 0.001) in maternal serum before delivery. In the umbilical cord serum, the B-inhibin concentration was 0.75 +/- 0.16 U/mL, whereas the I-inhibin concentration was 9.58 +/- 0.75 U/mL, which was much higher than that of B-inhibin (P less than 0.001). No difference was found in B-inhibin or I-inhibin levels in the serum samples collected separately from umbilical arteries and veins (P greater than 0.05). In addition, inhibin levels were measured in amniotic fluid and placental extract. In amniotic fluid, B-inhibin and I-inhibin concentrations were 2.37 +/- 0.35 and 8.01 +/- 0.55 U/mL, respectively. In the comparison, B-inhibin in amniotic fluid was 31.3% lower than that in maternal serum before delivery (P less than 0.05), but I-inhibin was 112.5% higher than that in the maternal serum (P less than 0.001). In the placental extract, the B-inhibin concentration was 12.80 +/- 0.35 U/g tissue, while the I-inhibin concentration was 33.86 +/- 2.93 U/g tissue, which was more than twice as high as the B-inhibin level (P less than 0.001). Our data provide further evidence that inhibin may be mainly produced in the placenta during pregnancy.

Adult↗
PubMed1991

Prolonged third stage of labor: morbidity and risk factors.

Although retained placenta is a major cause of postpartum hemorrhage, there is no general agreement regarding when manual placental extraction is indicated to prevent hemorrhage. We sought to determine the following: 1) what duration of the third stage of labor is abnormal, 2) what duration is associated with complications, and 3) what antecedent conditions are associated with prolonged third stage. We studied 12,979 consecutive, singleton vaginal deliveries over an 11-year period. Third-stage duration had a log-normal distribution, with a geometric mean of 6.8 minutes, a median of 6 minutes, and an interquartile range of 4-10 minutes. A third stage of 30 minutes or longer occurred in 3.3% of the deliveries. The incidence of postpartum hemorrhage, transfusion, and D&C remained constant in third stages less than 30 minutes, then rose progressively, reaching a plateau at 75 minutes. The increase in these complications after 30 minutes was observed with both spontaneously delivered and manually extracted placentas. In a logistic regression analysis, factors significantly associated with prolonged third stage included: preterm delivery (odds ratio 3.81), delivery in a labor bed (odds ratio 2.17), preeclampsia (odds ratio 1.76), augmented labor (odds ratio 1.47), and nulliparity (odds ratio 1.45). Because there was no increase in hemorrhage until the third stage exceeded 30 minutes, we suggest that in the absence of bleeding, manual placental extraction is not indicated until 30 minutes have elapsed.

Female↗
PubMed1979

Human placental immunoreactive corticotropin, lipotropin, and beta-endorphin: evidence for a common precursor.

The concentrations and molecular sizes of immunoreactive corticotropin (ACTH), lipotropin (LPH, beta LPH plus gamma LPH), gamma LPH, and beta-endorphin (beta END) were determined in human placental extracts. Serial dilutions of a water extract of placenta generated competitive binding curves parallel with that of the standard in each assay. The concentrations of ACTH, LPH, gamma LPH, and beta END were 3.3, 0.8, 0.7, and 1.1 ng/g wet weight of tissue, respectively. A partially purified extract applied to a Sephadex G-50 column contained high Mr components with ACTH, LPH, gamma LPH, and beta END immunoreactivities. The extract was applied to an immune affinity chromatography column consisting of affinity-purified (1-24)ACTH antiserum covalently bound to agarose. The material that adsorbed to the column and eluted with buffer containing sodium dodecyl sulfate had ACTH, LPH, and beta END immunoreactivities, indicating that there was a component or components containing antigenic determinants for all of these peptides. Sodium dodecyl sulfate/polyacrylamide gel electrophoresis of the affinity-purified placental extract revealed at least two high Mr components (Mr approximately 48,000 and 36,000) with all three immunoreactivities. These data suggest, but do not prove, that the placenta synthesizes ACTH, the LPHs, and beta END from a common precursor molecule.

Adrenocorticotropic Hormone↗